CIK 0001051514
SSKN STRATA Skin Sciences, Inc.
Insider trading from SEC Form 4. Last filing Nov 18, 2025. Close $0.00 on Oct 9, 2026, +100% from the 52-week low and -100% from the high.
In brief
STRATA Skin Sciences, Inc. (SSKN) has 13 SEC Form 4 filings on file from 8 insiders, the latest filed on Nov 18, 2025. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at SSKN. The newest: Samuel Rubinstein (director) bought $7,028 of stock on Nov 18, 2025, filed Nov 18, 2025, scored 25 (weak). The largest of the 4 shown: Samuel Rubinstein (director) sold $19k on Nov 17, 2025, scored 35 (weak).
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at STRATA Skin Sciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Samuel Rubinstein director buy | $7,028 5,000 shares | +133% | - | |
| 35Weak | Samuel Rubinstein director sell | $19k 14,094 shares | -79% | - | |
| 36Weak | Shmuel Gov COO buy | $8,956 20,000 shares | - | +45% from low-67% from high | |
| 15Weak | Samuel Rubinstein director sell | $320 1,000 shares | -1% | +50% from low-66% from high |
Transactions
Every row filed, 20 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 17, 2025 | Samuel Rubinstein director | SOpen-market sale Common Stock | -5,500 | $1.32 | $7,260 | 12,360 | Nov 18, 2025 |
| Nov 17, 2025 | Samuel Rubinstein director | SOpen-market sale Common Stock | -7,200 | $1.34 | $9,648 | 5,160 | Nov 18, 2025 |
| Nov 17, 2025 | Samuel Rubinstein director | SOpen-market sale Common Stock | -1,394 | $1.36 | $1,896 | 3,766 | Nov 18, 2025 |
| Nov 18, 2025 | Samuel Rubinstein director | POpen-market purchase Common Stock | +2,168 | $1.40 | $3,035 | 5,934 | Nov 18, 2025 |
| Nov 18, 2025 | Samuel Rubinstein director | POpen-market purchase Common Stock | +2,832 | $1.41 | $3,993 | 8,766 | Nov 18, 2025 |
| May 13, 2025 | John T Gillings Chief Accounting Officer | AGrant or award SSKN Stock Optionsderivative | +30,000 | $0.00 | $0 | 30,000 | May 15, 2025 |
| May 13, 2025 | Shmuel Gov Chief Operating Officer | AGrant or award SSKN Stock Optionsderivative | +40,000 | $0.00 | $0 | 137,125 | May 15, 2025 |
| May 13, 2025 | Dolev Rafaeli Chief Executive Officer | AGrant or award SSKN Stock Optionsderivative | +58,000 | $0.00 | $0 | 232,557 | May 15, 2025 |
| Oct 29, 2024 | Christina L Allgeier director | AGrant or award SSKN Stock Optionsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 30, 2024 |
| Dec 1, 2023 | Shmuel Gov COO | POpen-market purchase SSKN Common Stock | +14,338 | $0.44 | $6,309 | 14,338 | Dec 5, 2023 |
| Dec 1, 2023 | Shmuel Gov COO | POpen-market purchase SSKN Common Stock | +562 | $0.45 | $253 | 14,900 | Dec 5, 2023 |
| Dec 1, 2023 | Shmuel Gov COO | POpen-market purchase SSKN Common Stock | +300 | $0.46 | $138 | 15,200 | Dec 5, 2023 |
| Dec 1, 2023 | Shmuel Gov COO | POpen-market purchase SSKN Common Stock | +4,800 | $0.47 | $2,256 | 20,000 | Dec 5, 2023 |
| Nov 21, 2023 | Shmuel Gov COO | AGrant or award Employee Stock Optionderivative | +416,250 | $0.00 | $0 | 971,250 | Nov 22, 2023 |
| Nov 21, 2023 | Christopher Lesovitz Chief Financial Officer | AGrant or award Employee Stock Optionderivative | +337,500 | $0.00 | $0 | 787,500 | Nov 22, 2023 |
| Nov 16, 2023 | Samuel Rubinstein director | SOpen-market sale Common Stock | -1,000 | $0.32 | $320 | 177,602 | Nov 20, 2023 |
| Oct 30, 2023 | Dolev Rafaeli Chief Executive Officer | AGrant or award SSKN Stock Optionsderivative | +1,745,569 | $0.00 | $0 | 1,745,569 | Oct 30, 2023 |
| Oct 26, 2023 | Wayne Cafran director | AGrant or award SSKN Stock Optionsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 27, 2023 |
| Oct 26, 2023 | Samuel Rubinstein director | AGrant or award SSKN Stock Optionsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 27, 2023 |
| Oct 26, 2023 | Irit Yaniv director | AGrant or award STRATA Stock Optionsderivative | +20,000 | $0.00 | $0 | 20,000 | Oct 27, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Christina L Allgeierdirector
- Wayne Cafrandirector
- John T GillingsChief Accounting Officer
- Shmuel GovCOO
- Christopher LesovitzChief Financial Officer
- Dolev RafaeliChief Executive Officer
- Samuel Rubinsteindirector
- Irit Yanivdirector
Questions about SSKN
Answered from the filings on this page, as of the latest one.
Are insiders buying SSKN?
No. In the last 90 days no insider at STRATA Skin Sciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade SSKN on the open market?
Samuel Rubinstein (director) bought $7,028 of SSKN on Nov 18, 2025 and filed the Form 4 on Nov 18, 2025. InsiderTell scored 25 (weak).
How many insiders file Form 4 at STRATA Skin Sciences, Inc.?
8 people have filed a Form 4 at STRATA Skin Sciences, Inc., among them Christina L Allgeier (director), Wayne Cafran (director), John T Gillings (Chief Accounting Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.